Cours BioSyent Inc. Other OTC
Actions
BIOYF
CA0906901081
Produits pharmaceutiques
CA 2024 * | 35 M 25,67 M 23,15 M | CA 2025 * | 38,7 M 28,38 M 25,6 M | Capitalisation | 107 M 78,24 M 70,58 M |
---|---|---|---|---|---|
Résultat net 2024 * | - | Résultat net 2025 * | - | VE / CA 2024 * | 3,05 x |
Trésorerie nette 2024 * | - 0 0 | Trésorerie nette 2025 * | - 0 0 | VE / CA 2025 * | 2,76 x |
PER 2024 * |
16,5
x | PER 2025 * |
14,4
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 60,63% |
Dernier transcript sur BioSyent Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
René C. Goehrum
CEO | Chief Executive Officer | 64 | 01/01/96 |
Robert March
DFI | Director of Finance/CFO | - | 10/09/18 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/14 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 08/01/18 |
René C. Goehrum
CEO | Chief Executive Officer | 64 | 01/01/96 |
Peter Lockhard
BRD | Director/Board Member | 60 | 01/06/02 |
Varia. 1 janv. | Capi. | |
---|---|---|
+40,73% | 739 Md | |
+32,83% | 598 Md | |
-6,30% | 353 Md | |
+15,15% | 318 Md | |
+4,05% | 285 Md | |
+15,00% | 240 Md | |
+9,78% | 210 Md | |
-5,52% | 206 Md | |
+6,17% | 164 Md |